CBX4

Across TCGA pan-cancer cohorts, CBX4 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CBX4 data layer compared with 18 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CBX4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CBX4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

LIHC, LUAD, and SARC are the cancer types where CBX4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	III,IV	0.051	0.650	<.001	30	view →
LUAD	OS	Median	II,III,IV	0.109	0.750	<.001	30	view →
SARC	DFS	Median	All	0.145	0.635	.002	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.030	6	view →
COAD	DFS	Median	All	0.183	0.696	.004	6	view →
BLCA	DFS	Median	All	0.826	0.327	.039	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CBX4–LIHC (OS)

Open the LIHC breakdown →